Overview

This trial is active, not recruiting.

Condition pancreatic adenocarcinoma
Sponsor Centre Hospitalier Departemental Vendee
Start date October 2013
End date December 2015
Trial size 1204 participants
Trial identifier NCT01989624, CHD064-13

Summary

Few data are currently available in the literature on pancreatic adenocarcinoma in France. About 8,000 new cases each year in France. The 5-year survival for all stages combined is <5%. This is the only digestive cancer in which mortality / incidence ratio is 98%.

Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life.

The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country.

The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm

Primary Outcomes

Measure
Survival
time frame: patient death (following during 5 year)

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Living in France - Pancreatic adenocarcinoma histologically or cytologically proven - primary diagnosis - Agreed to participate Exclusion Criteria: - Suspected pancreatic adenocarcinoma histologically or cytologically unproven - Refused to participate

Additional Information

Official title PAncreatic Adenocarcinoma in Hospital
Principal investigator Roger FAROUX, PH
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by Centre Hospitalier Departemental Vendee.